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Charcot‑Marie‑Tooth type 1A (CMT1A) is a dysmyelinating disease of the peripheral nervous system that results in a slow progressive 
weakening and wasting of the distal muscles of the upper and lower limbs. Despite extensive research and clinical trials there is still 
no treatment for CMT1A that results in complete neurological improvement. Recent studies investigating various pharmacological 
modulators of adenylyl cyclase activity, including ascorbic acid and ligands of G protein‑coupled receptors (GPCRs), provide hope for 
future treatments of this type of hereditary motor and sensory neuropathy. A review of mechanisms of action of several compounds 
tested for CMT1A in pre‑clinical and clinical studies ascorbic acid, onapristone, PXT3003 (baclofen, naltrexone, and sorbitol), and 
ADX71441, very clearly indicates an important role for adenylyl cyclase activity and GPCRs in the pathomechanism of the disease. 
Metabotropic γ‑aminobutyric acid receptors (GABABR), subtype mu (µ) opioid receptors (MOR), and muscarinic acetylcholine receptors 
(mACh) appear to be particularly significant in both pathogenesis and treatment, and their activation may exert a similar and synergistic 
effect on the physiology of Schwann cells as well as neurons. These receptors participate in proliferation and differentiation of Schwann 
cells and influence excitatory transmission in neurons. We also hypothesize that onapristone might act through a  non‑classical 
mechanism via membrane progesterone receptor (mPR) and cAMP signaling. This review endeavors to outline a  pathway leading 
inversely from therapy to an indispensable role for adenylyl cyclase activity and GPCRs in the modulation of dosage sensitive peripheral 
myelin protein (PMP22) gene expression. 
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INTRODUCTION
Major advancements in our understanding of the 
pathomechanism and genetic background of peroneal 
muscular atrophy have been achieved since Charcot and 
Marie, in Paris, and Tooth, in London, first described the 
heterogeneous syndrome in 1886. More than 80 years 
later Dyck and Lambert (1968), on the basis of neurolog‑
ic, genetic, and electrophysiological findings, differen‑
tiated two main types of hereditary motor and sensory 
neuropathy (HMSN): type I (demyelinating) and type II 
(axonal), also known as Charcot‑Marie‑Tooth disease 
type 1 (CMT1) and type 2 (CMT2), respectively (Genig‑
nani and Marbini 2001). With the advent of molecular 
biology it has become clear that genetic heterogeneity 
between CMT types exists. Further development of new 
molecular biological techniques enabled the advance‑
ment of molecular genetic studies leading to the identi‑
fication of nearly 100 genes responsible for many types 
of CMT disease. Charcot‑Marie‑Tooth disease type 1A 
(CMT1A) constitutes almost 60% of all known CMT cases 
(Liu et al. 2014). Disease onset occurs in the first decade 
of life and is usually identified because of frequent falls 
and clumsiness of gait. Initial symptoms are recognized 
as high‑arched feet, which is a consequence of atrophy 
of the intrinsic feet muscles. Usually CMT disease begins 
with a slow progressive wasting and weakening of the 
distal muscles of the lower limbs. The atrophy spreads 
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to other muscle groups of the lower limbs, i.e., perone‑
al, anterior tibialis, and triceps, yielding a characteristic 
phenotype of inverted bottle legs. Muscle atrophy can 
also affect intrinsic muscle groups of the hands, spread‑
ing to 1/3 of the lower parts of the forearms. Tactile 
sensory disruption may be concomitant and observed 
in gloves and stockings areas (Kochański 2008). CMT1A 
disease is characterized by significant clinical hetero‑
geneity in terms of the age of onset, degree of muscle 
weakness, comorbidity with other symptoms, and an an‑
ticipation (De Jonghe 1998). 
The primary feature of CMT1A disease is a decrease 
of conduction velocity in both motor and sensory fi‑
bers to about 20 m/s. In sural nerve biopsy, numerous 
tomaculas (loops of unfolded myelin) surrounding de‑
myelinating and remyelinating fibers are observed. De‑
spite very heterogeneous clinical features, the genetic 
causes of CMT1A disease are relatively homogenous. 
In an overwhelming majority of cases, CMT1A disease 
is caused by a large duplication located on the short 
arm in region 17p11.2‑p12, which is occupied by the 
PMP22 gene encoding 22 kDa peripheral myelin protein 
(PMP22) – one of the major protein constituents of the 
myelin sheath of peripheral nervous system (PNS) neu‑
rons (Lupski et al. 1991, Patel et al. 1992, Raeymaekers 
et al. 1991). However, in 1993 a point mutation in the 
PMP22 gene was identified for the first time (Roa et al. 
1993). In this report an amino acid substitution (S79C) 
was shown to have the same phenotypic effect as du‑
plication of the PMP22 gene. Additionally, point muta‑
tions were absent in patient groups with duplication of 
PMP22 (Warner et al. 1996).
Gene dosage effect of PMP22 in CMT1A disease
A gene dosage effect has been hypothesized and is 
generally accepted as an underlying mechanism of CM‑
T1A disease, proposed by Lupski et al. (1992), and is de‑
fined by an increase in expression of PMP22 mRNA in 
patients with CMT1A phenotype (Schenone et al. 1997, 
Yoshikawa et al. 1994). Although a gene dosage effect 
represents the most likely molecular mechanism under‑
lying CMT1A, it does not fully explain the pathogenesis 
of the disease. Indeed, duplication of a large submicro‑
scopic region of DNA (1.5 Mb), observed at both the tran‑
scriptional and translational level, is certainly involved 
in the pathogenesis of CMT1A disease, but phenotype se‑
verity seems to correlate only loosely and reaches a pla‑
teau above a certain level. In light of the hypothesis, we 
could assume that patients with four copies of the PMP22 
gene are predicted to be affected more severely than 
those with three copies; however, they do not actually 
manifest a more severe phenotype. Though, in a subpop‑
ulation of CMT1A patients, a triplication causing a more 
severe phenotype was found (Di Vincenzo al. 2014). It 
is clear that broad heterogeneity in the clinical pheno‑
type of CMT1A is also observable, with PMP22 mRNA and 
protein levels being highly variable among patients and 
lacking correlation with disease severity and clinical 
outcome measures (Katona et al. 2009, Lewis et al. 2013, 
Nobbio et al. 2014, Scherer and Wrabetz 2008, Visigalli 
et al. 2016). 
The gene dosage effect hypothesis has been fully 
confirmed in animal models where phenotype severity 
correlated with PMP22 gene copy number (Schenone et 
al. 1997, Sereda et al. 2003). However, the animal mod‑
els were developed by integration of extra copies of the 
PMP22 gene into their genomes (Huxley et al. 1996, 1998, 
Magyar et al. 1996, Robaglia‑Schlupp et al. 2002, Sere‑
da et al. 1996, Verhamme et al. 2011). Additionally, some 
data indicate that duplication of a small region (186 kb) 
downstream of the dosage sensitive region of the PMP22 
gene is sufficient to cause the phenotype of the neurop‑
athy, as recently found in six families. Such copy number 
variation (CNV) is not usually assessed during routine 
diagnostic screens for CMT1A because copy numbers of 
PMP22 are normal (Weterman et al. 2010). 
Thus, no biological basis for clinical variability of 
CMT1A is known. However, a recent study of a large co‑
hort of CMT1A/HNPP‑affected patients conducted by 
Sinkiewicz‑Darol et al. (2015) determined that the LITAF 
I92V sequence variant predisposes patients to an earlier 
age of onset of CMT1A as well as hereditary neuropathy 
with liability to pressure palsies (HNPP) diseases. It is 
noteworthy that HNPP is characterized by a single copy 
of PMP22 (Chance et al. 1993), but point mutations have 
also been reported (Nicholson et al. 1994). Moreover, 
Visigalli et al. (2016), focusing on alternative splicing of 
PMP22, found three new gene transcripts in human sural 
nerve biopsies and also demonstrated altered expression 
of Qki in rats, which is a critical splicing regulator during 
the myelination process. These data suggest a possible 
role for alternative splicing in the clinical variability of 
CMT1A neuropathy.
Drug therapies in CMT1A
In laboratory transgenic animals, Pmp22 gene copy 
number has been shown to correspond with the clin‑
ical course of neuropathy (Schenone et al. 1997, Suter 
and Nave 1999). Moreover, an experimental approach 
involving reduction of Pmp22 expression resulted in an 
improved clinical course of CMT in transgenic mice and 
rats (Passage et al. 2004, Sereda et al. 2003), which led to 
large clinical trials. However, the human trials did not 
confirm the findings from animal models, probably due 
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to a lack of correlation between gene dosage and clinical 
outcome of CMT1A (Sinkiewicz‑Darol et al. 2015). 
Currently available drug therapies for CMT1A aim 
to abolish the dosage effect/toxic gain of function of 
the overexpressed PMP22 gene (Table I). Although phar‑
macological therapies aimed toward decreasing gene 
dosage of PMP22 failed or showed some minor effect, 
they have been very informative in terms of unraveling 
CMT1A pathogenesis. Here we describe various phar‑
macological approaches in the treatment of CMT1A 
disease that modulate adenylyl cyclase activity. A com‑
plete list of currently available compounds tested in 
CMT1A therapy has previously been published by Ekins 
et al. (2015).
Ascorbic acid
Initial CMT1A therapy attempts involved ascorbic 
acid (AA, vitamin C), which is predominantly known 
for its antioxidant properties. However, the mechanism 
of action of AA is multifaceted due to its more than 20 
metabolites, which differ in various tissues (Passage et 
al. 2004). Besides its role as an antioxidant, AA has an 
important neuromodulatory role in the brain, aiding 
in the release of some neurotransmitters while also in‑
hibiting neurotransmitter binding to receptors (Rosa et 
al. 2005). Although the exact mechanism by which AA 
exerts its action remains unclear, a number of studies 
have recently demonstrated that AA can regulate the 
expression of a battery of genes encoding extracellular 
matrix proteins and myelin proteins (Belin et al. 2010). 
An experiment using neuron‑Schwann cell co‑culture 
supplemented with AA showed that AA plays a vital 
role in in vitro myelination (Clark and Bunge 1989). In‑
deed, Passage et al. (2004) demonstrated in a transgen‑
ic mouse model that high doses of AA decreased Pmp22 
expression and ameliorated CMT1A phenotype in terms 
of functional and histopathological findings. This was 
further confirmed by Kaya et al. in 2007, who addition‑
ally determined the mechanism by which AA reduced 
Pmp22 expression (Kaya et al. 2008). AA was proposed 
as a competitive inhibitor of adenylyl cyclase activity 
that exerts an effect on intracellular cyclic adenosine 
monophosphate (cAMP). Additionally, the inhibitory 
effect of AA was abolished by administration of vita‑
min A or E (Kaya et al. 2008). Promising findings in 
experimental models resulted in various clinical trials 
of AA administration in CMT1A patients. However, the 
first and largest study, conducted over two years, re‑
ported no significant differences between AA and pla‑
cebo groups (Pareyson et al. 2011). Although clinical 
studies revealed that AA treatment had no impact on 
CMT1A, it is thought to carry out an important func‑
tion in peripheral nerve myelination and possibly in 
remyelination (Gess et al. 2011). An informative and 
well‑designed experiment was conducted by Gess et al. 
(2011) who studied sodium‑dependent vitamin C trans‑
porter 2‑heterozygous (SVCT2+/‑) mice. In this study, 
they showed reduced expression of SVCT2 mRNA and 
protein levels as well as decreased AA concentrations 
in sciatic nerves of KO mice. Histopathology of sciatic 
nerve also revealed reduced myelin thickness, which 
was reflected in sensorimotor performance and elec‑
trophysiological tests of the studied animals. Further‑
more, they provided evidence for defects in collagen 
synthesis both in sciatic nerves and in Schwann cell 
cultures under SVCT2‑inhibiting conditions. Interest‑
ingly, SVCT2 mutation is associated with myelin pro‑
tein zero (MPZ) reduction and simultaneously with an 
Table I. Compounds tested in preclinical and clinical settings for CMT1A that modulate adenylyl cyclase activity and cAMP levels. 
Compound Targeted GPCR Research stage Outcome Reference
Ascorbic Acid –
Pre‑clinical
Improvement  
(myelination, myelin 
thickness, PMP22 level)
Passage et al. 2004
Clinical No improvement Pareyson et al. 2011
Onapristone* mPR Preclinical Improvement  (myelination, PMP22 level) Sereda et al. 2003
PXT3003
 Baclofen
 Naltrexone
 Sorbitol
 
GABAB
opioid receptor
muscarinic acetylcholine receptor
Pre‑clinical Improvement  (myelination, PMP22 level) Chumakov et al. 2014
Phase 2 clinical trial Minor improvement Attarian et al. 2014
ADX71441 GABAB Pre‑clinical
Improvement 
(myelination, PMP22 level, 
electrophysiology)
Addex Therapeutics 2013
* Onapristone is hypothesized by author A.J.K. of this manuscript as an mPR modulator which has not yet been confirmed in any study.
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increase (2.8‑fold), though not statistically significant, 
in (mRNA) Pmp22 expression levels (Gess et al. 2011). 
The statistically insignificant rise in Pmp22 expression 
might be sufficient to yield a disease phenotype. This 
fact is interesting when considered together with AA’s 
function in modulating extracellular matrix (ECM). AA 
is necessary for collagen synthesis in the PNS and col‑
lagen in turn is vital for correct myelination (Petersen 
et al. 2015). Moreover, it has been suggested that an in‑
teraction between ECM and the expression of myelin 
genes is possible (Chernousov et al. 2008). AA would be 
necessary for the myelination process by an, as of yet, 
unclear mechanism. However, myelination might be 
controlled by non‑canonical cAMP signaling, including 
exchange protein activated by cAMP (EPAC) exerting 
its activity via direct binding to cAMP, soluble adeny‑
lyl cyclase (sAC), which is activated independently of 
GPCRs, and the highly conserved orphan GPCR GPR126 
that controls myelination via cAMP (Bacallao and Mon‑
je 2015, Monje 2015).
GPR126 is known to interact with the extracellular 
matrix proteins collagen and laminin‑211 (Monk et al. 
2009, 2011) and may constitute a functional link between 
two elements (ECM and expression of myelin genes). 
Onapristone‑progesterone receptor antagonist 
Progesterone is considered to be a neuroactive ste‑
roid because it is synthesized in the nervous system 
by glial cells independently of endocrine production. 
The literature suggests a mutual interplay between the 
GABAergic system (via GABAA and GABAB receptors) 
and neuroactive steroids, such as progesterone and its 
derivatives. Neuroactive steroids act as amplifiers of 
GABA neurotransmission (Magnaghi et al. 2006). Pro‑
gesterone elicits its action via two mechanisms: genom‑
ic – through the specific binding of progesterone re‑
ceptor (PR) to progesterone‑responsive elements (PRE) 
and further stimulation of activity of the promoters of 
myelin protein genes and non‑genomic – through acti‑
vation of signaling pathways that may be mediated by 
membrane‑associated PRs (Singh et al. 2013). The MPZ 
promoter, PMP22 promoter 1, and PMP22 exon1 do not 
contain PREs. Thus, progesterone may indirectly acti‑
vate these promoters by inducing a Schwann cell‑spe‑
cific transcription factor (Desernaud et al. 1998) and in‑
creasing mRNA concentrations of myelin genes (Melca‑
ngi et al. 1998). Moreover, derivatives of progesterone, 
dihydroprogesterone (DHP) and tetrahydroprogester‑
one (THP or allopregnenolone), increased myelin gene 
expression by activation of GABAA steroid receptors on 
Schwann cells in both in vitro and in vivo experiments 
(Melcangi et al.1999). THP is a steroid that is unable to 
bind PR, but actively interacts with some components 
of the GABAA receptor. THP and the progestogens P and 
DHP in turn can influence the expression of GABAB sub‑
units in Schwann cells (Magnaghi et al. 2006). Impor‑
tantly, Zhu et al. (2003a, 2003b) discovered and classi‑
fied three subtypes of membrane progesterone recep‑
tors (mPR), which are GPCRs belonging to the progestin 
and adipoQ receptor family (PAQR) and mediate rapid 
action of progestogens in reproductive tissues and in 
the nervous system (Thomas and Pang 2012). Sereda et 
al. (2003) conducted an experiment using transgenic 
rats that suggested the PR of myelin‑forming Schwann 
cells is a promising pharmacological target for therapy 
of CMT1A. In the study, administration of progesterone 
increased the expression of myelin genes in the sciatic 
nerve and resulted in enhanced Schwann cell patholo‑
gy. In contrast, administration of onapristone (proges‑
terone receptor antagonist) reduced overexpression of 
Pmp22, ameliorating the CMT1A phenotype (Sereda et 
al. 2003). These findings were confirmed by Meyer zu 
Horste et al. (2007). However, the latter reported that 
onapristone did not improve myelin sheath thickness. 
Clinical trials have not been started due to severe side 
effects of anti‑progesterone treatment (Robertson et 
al. 1999). In light of these data it should be considered 
that treatment with anti‑progesterone derivatives like 
THP may be more efficient than anti‑progesterone it‑
self, as THP can exert its action not only via classical 
PR but also via GABAA receptors (Melcangi et al. 1999), 
which is certainly a more complex approach. Addition‑
ally, Schwann cells are able to synthesize progesterone 
locally and thus abolish the effect of onapristone by 
increasing the concentration of progesterone within 
the cell or possibly signaling via the GABA‑ergic sys‑
tem may overwhelm the PR pathway. We also cannot 
exclude the possibility that onapristone exerts its ac‑
tion via mPR in Schwann cells and neurons. The impor‑
tance of alternative pathways of progesterone signal‑
ing is supported by the observation of Jung‑Testas et 
al. (1999) who showed that the structure of peripheral 
nerves was normal in PR knockout (PRKO) mice. 
PXT3003
PXT3003 is a novel combination of three drugs – ba‑
clofen, naltrexone, and sorbitol – that was shown to low‑
er Pmp22 ransgenic rats (Chumakov et al. 2014). Addi‑
tionally, GPCRs targeted by the compound are expressed 
not only in Schwann cells but also in peripheral neurons, 
which indicates a wider mechanism of action (Stein and 
Lang 2009).
PXT3003 has already passed phase 2 clinical trials, 
which confirmed the safety and tolerability of low dos‑
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es of PXT3003 in the treatment of CMT1A affected indi‑
viduals and showed improvement beyond stabilization 
(Attarian et al. 2014). Further investigation is current‑
ly being conducted in phase 3 clinical trials. Baclofen 
is a derivative of GABA and exerts its action by GABAB 
receptors. It is used as a spasmolytic drug in multiple 
sclerosis (Hudgson et al. 1972) as well as in alcohol ad‑
diction therapy (Addolorato et al. 2002). Naltrexone is 
a reverse agonist of opioid receptors used in treatment 
of opioid (Resnick et al. 1978) and alcohol dependence 
(Morris et al. 2018). Its mechanism of action is exerted 
primarily via μ‑opioid receptors (MOR). Sorbitol may 
act as a chaperone and/or bind muscarinic acetylcho‑
line GPCRs (Liu et al. 2005). 
ADX71441 
Recently, a positive allosteric modulator (PAM) 
of GABAB receptor N‑(5‑(4‑(4‑chloro‑3‑fluorobenzyl)
‑6‑methoxy‑3,5‑dioxo‑4,5‑dihydro‑1,2 ,4‑tr iazin‑ 
2(3H)‑yl)‑2‑fluorophenyl)acetamide, termed ADX71441, 
was studied in the transgenic CMT rat model, model‑
ing symptoms in CMT1A patients and characterized 
by overexpression of Pmp22 at transcriptional level, 
decreased nerve conduction velocity, and lower grip 
strength. Peripheral nerves of ADX71441‑treated rats 
exhibited downregulation of Pmp22 mRNA, reduction of 
hypomyelinated axons, and increased compound mus‑
cle action potentials (CMAP) in comparison with the 
Fig. 1. (A) Determination of Schwann cell fate via ascorbic acid and GPCR modulators. Administration of ascorbic acid and pharmacological activation 
of GPCRs (GABAB, opioid receptor or muscarinic receptor) in Schwann cell membrane leads to transmembrane adenylyl cyclase inhibition and 
concomitant decrease in cAMP level, inhibition of PKA phosphorylating activity, and finally effective suppression of myelin genes’ transcription, 
which in turn shifts Schwann cells into proliferative state and inhibits the differentiation and myelination process. Thus, low levels of cAMP promote 
proliferation, while high levels promote differentiation of Schwann cells. (EC) extracellular; (IC) intracellular; (AC) adenylyl cyclase; (ATP) adenosine 
triphosphate; (cAMP) cyclic adenosine monophosphate; (PKA) phosphokinase A; (CREB) cAMP responsive element binding protein; (CRE) cAMP 
response element; (PMP22) peripheral myelin protein gene; (Egr2) (also termed Krox20) early growth response 2.
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control group (Dyer 2013). It is noteworthy that neither 
onapristone nor PXT3003 increased CMAP, which is an 
important indicator of neuromuscular transmission. 
ADX71441 acts as an allosteric modulator amplifying 
the orthosteric agonist effect on its metabotropic re‑
ceptor either by enhancing the affinity of binding or 
the functional efficacy (May et al. 2007). It has previ‑
ously been approved for phase 1 clinical trials in over‑
active bladder (Kalinichev et al. 2014) as well as for 
anxiety, pain, and spasticity treatment (Kalinichev et 
al. 2017). 
GPCRS influence Schwann cell fate and excitatory 
transmission in neurons
The GPCR superfamily constitutes the largest class 
of functionally selective drug therapy targets for PNS 
diseases (for review see Mogha et al. 2016). Data ob‑
tained from both pre‑clinical and clinical trials allows 
for analysis of the mechanism of action of several re‑
ceptors and downstream signaling pathways, and thus 
explain their role in the physiology and pathology of 
neural cells. A clear and essential role of GPCRs in the 
pathomechanism of CMT1A disease has been demon‑
strated. Particularly significant to both pathogenesis 
and treatment, are the GABABRs, the MORs, and possi‑
bly type 2 muscarinic receptors (M2), the activation of 
which may exert a similar and synergistic effect on the 
physiology of neurons (Christie and North 1988) as well 
as Schwann cells. We also hypothesize that mPR and 
cAMP signaling could be modulated by onapristone, as 
described earlier in this text.
The common denominator in signal transduction by 
GPCRs is cAMP. Activation of the above‑mentioned re‑
ceptors inhibits adenylyl cyclase, which does not convert 
ATP into cAMP. Low levels of cAMP inhibits expression 
of transcription factors and myelin genes, switching the 
Schwann cell into a proliferative state (Fig. 1A). More‑
over, cAMP maintains a balance between other signaling 
pathways like PI3K‑AKT and MEK‑ERK and integrates 
stimuli derived from other receptors, i.e., tyrosine ki‑
nases activated by neuregulin 1 (NRG1), which provides 
a proliferation or myelination signal in accordance with 
the concentration of cAMP. Activation of GPCRs can also 
directly influence the kinetics of potassium and calcium 
ion channels important to excitatory neurotransmission 
as well as indirectly influence by lowering cAMP levels 
(Fig. 1B).
GABAB receptors
GABARs are primarily known for their inhibitory ac‑
tions on excitatory transmission in neurons, but they 
also have an important role in Schwann cell prolifera‑
tion and myelination. A GABAR agonist, GABA, increases 
or decreases the synthesis of PMP22 protein, depending 
on the receptor involved (GABAA or GABAB). The acti‑
vation of ionotropic GABAA receptors exerts a stimula‑
tory effect on PMP22 gene expression (Magnaghi et al. 
2001). Activation of metabotropic GABAB receptors leads 
Fig. 1. (B) Activation of GPCRs (directly) and low level cAMP (indirectly – not shown in the Figure) in neurons influence potassium and calcium ion 
channel kinetics causing closing and opening, respectively, which evokes hyperpolarization (K+) of the cell and inhibits axonal transmission of 
neuronal stimuli (Ca2+). 
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to decreased levels of PMP22 and MPZ in Schwann cells 
(Magnaghi et al. 2004, Melcangi et al. 2005). This is the 
case, at least, for Schwann cells in culture absent of neu‑
rons. However, Corell et al. (2015) suggested that GABAB 
receptor is not involved in developmental Schwann cell 
proliferation because neither baclofen (GABAB receptor 
agonist) nor CGP55485 (GABAB receptor antagonist) had 
an effect on proliferation of Schwann cells, which were 
co‑cultured with DRG neurons. In this model myelin as‑
sociated glycoprotein (MAG) and myelin basic protein 
(MBP) mRNAs were increased, suggesting that GABAB 
receptor activation controls myelin protein expression 
and myelination itself. Importantly, upregulation of 
GABAB receptor occurred after nerve crush injury. This 
is interesting because GABAB activation decreased cAMP 
levels in Schwann cells as well as in neurons and addi‑
tionally inhibited neuronal excitability and, thus, does 
not promote myelination. Since activation of the inhib‑
itory GABAergic pathway promotes amelioration of the 
CMT1A phenotype, one question is whether over‑acti‑
vation of the glutamatergic pathway may be involved 
in the pathomechanism of CMT1A. If so, we should also 
consider the glutamatergic pathway as a potential novel 
target for drug therapies in CMT1A and other demyelin‑
ating diseases of the nervous system.
Opioid receptors
By targeting opioid receptors it is possible to mod‑
ulate calcium and potassium ion channels. Opioids ex‑
ert inhibitory effects on neuronal excitability by regu‑
lating Kir3 potassium channels and inhibiting calcium 
conductance (Al‑Hasani 2011). Despite their function in 
neuronal excitability, opioid receptors are expressed on 
CNS oligodendrocytes, and the role of the opioid system 
in myelination is poorly understood. Vestal‑Laborde et 
al. (2014) reported that perinatal exposure of rat pups 
to the opioid methadone elevated levels of the myelin 
proteins MBP, PLP, and MOG in the brain and increased 
the number of myelinated axons. Thus, per analogiam, 
myelin protein expression could be changed in the PNS 
through opioid receptor modulation. 
Several studies have shown that all subtypes of 
opioid receptors are negatively coupled to adenylyl 
cyclase and suppress cAMP formation via activation 
of GTP‑binding proteins (Gi/o). However, Russell et al. 
(2001) demonstrated that activation of κ‑opioid recep‑
tors in neurons of rabbit iris‑ciliary body can evoke 
both stimulatory and inhibitory effects on the cAMP 
pathway depending on the concentration being used. 
Production of cAMP was inhibited at high concentra‑
tions and stimulated at low concentrations of brem‑
azocine (κ‑opioid receptor agonist) administration. 
A similar response of opioid receptor activation on 
cAMP level was observed by Dziedzicka‑Wasylewska 
and Przewłocki (1995) who showed that administra‑
tion of U50,488H (κ‑opioid receptor agonist) as well 
as morphine (µ‑opioid receptor agonist) increased the 
cAMP level in rat hippocampal slices. These observa‑
tions lend to the possibility that naltrexone (reverse 
agonist of opioid receptor) could also have a bipha‑
sic effect on cAMP level, suppressing its production 
at low doses. In fact, opiate withdrawal leads to a sig‑
nificant increase in cAMP‑dependent protein kinase 
(PKA) and cAMP response element binding protein 
(CREB) in noradrenergic nuclei (Guitart et al. 1992), 
the expression of which was shown to be decreased in 
rats that received low doses of naltrexone in drinking 
water (Mannelli et al. 2004). 
Muscarinic acetylcholine receptors
Schwann cells, by expressing muscarinic acetylcho‑
line receptors M1, M2, M3, and M4 (for comprehensive 
review see Fields et al. 2017) participate in cholinergic 
signaling within the PNS (Loreti et al. 2006). The most 
abundant GPCR found in Schwann cell membranes is the 
M2 receptor. Morphometric and ultrastructural analysis 
of M2/M4 knock‑out mouse sciatic nerve revealed al‑
tered myelin organization and degenerated axons (Ug‑
genti et al. 2014). Additionally, cAMP production was in‑
hibited by activation of M2 and M4 receptors, which in 
turn abolished Ca2+ conductance (Eglen 2006). This effect 
is similar to the action of opioid receptors, as mentioned 
previously. Uggenti et al. (2014) also showed that in vi-
tro activation of M2 receptor, by its agonist arecaidine, 
upregulated transcription factors Sox10 and Krox20, in‑
volved in the promyelinating phase, and simultaneous‑
ly downregulated proteins c‑Jun, Notch‑1 and Jagged‑1, 
which in turn maintain Schwann cells in an undiffer‑
entiated state. It is important to note that upregula‑
tion of the transcription factor c‑Jun in Schwann cells 
protected sensory neurons in a mouse model of CMT1A 
(Hantke et al. 2014). Thus, the cell cycle is arrested by 
M2 receptor activation, which inhibits cell proliferation 
and at the same time promotes cell differentiation and 
expression of myelin proteins (Uggenti et al. 2014). This 
is of interest because low levels of cAMP, induced by M2, 
act as a proliferation signal for Schwann cells and sug‑
gests that M2 receptor stimulation may exert a dual/
multiple effect: lowering the level of proliferation‑pro‑
moting cAMP and upregulating transcription factor Egr2 
(Krox‑20), which in turn promotes expression of myelin 
genes. However, another more convincing explanation 
is possible, that an upregulation of Krox‑20 and Sox10 is 
likely independent of cAMP signaling or may use other 
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pathways or downstream effectors such as the previous‑
ly mentioned EPAC, sAC, and GPR126 (Fig. 1). The second 
explanation is that d‑sorbitol acts via different subtypes 
of muscarinic receptor, i.e., M1, M3, or M5, whose signal 
stimulates via Gq protein’s phospholipase C activity and 
calcium signaling, thus increasing intracellular calcium 
concentration and leading to the expression of myelin 
genes (Fields et al. 2017). It is noteworthy that neureg‑
ulin 1 isoform III (NRG1), which was shown to alleviate 
CMT1A phenotype in rats, influenced the activity of the 
PLC pathway but through a different type of receptor – 
tyrosine kinase (Fledrich et al. 2014). Additionally, cAMP 
signaling is vital in switching β‑neuregulin 1 (NRG1‑β) 
from a proliferative signal to a myelin differentiation 
signal (Arthur‑Farraj et al. 2011). cAMP could also switch 
d‑sorbitol action in the same manner. 
It seems that proliferation rather than differenti‑
ation relies on the activation of transmembrane ad‑
enylyl cyclase (tmAC). In turn, myelination may be 
controlled by non‑canonical cAMP signaling including 
EPAC, sAC, which is activated independently of GPCRs, 
and GPR126, a highly conserved orphan GPCR that con‑
trols myelination via cAMP (Bacallao and Monje 2015, 
Monje 2015).
This can partially explain why therapy aiming at 
modulation of cAMP levels via GPCRs may not be as 
effective as predicted. Drugs inhibit tmAC without in‑
hibiting its soluble form. Overactivity of sAC in CMT1A 
patients might lead to downstream signaling, inducing 
transcription factors responsible for overexpression of 
myelin genes including PMP22. The total effect of phar‑
macological therapy with the use of GPCR ligands could 
depend on the canonical (via tmAC) and non‑canonical 
(via EPAC, sAC, and GPR126) pathway signaling ratio. 
To date, only a few GPCRs that could be used for fu‑
ture dysmyelinating disease therapy have also been de‑
scribed in Schwann cells: GPR126/ADGRG6 (adhesion 
family member interacting with laminin‑211, collagen 
IV, and Prpc) (Küffer et al. 2016, Paavola et al. 2014, Pe‑
tersen et al. 2015), GPR44 and LPA1 (rhodopsin family 
members) interacting with prostaglandin D2 (Trimar‑
co et al. 2014) and lysophosphatidic acid (Anliker et 
al. 2013), respectively. For a comprehensive review see 
Mogha et al. (2016). 
cAMP signaling in the pathomechanism of CMT1A
It seems that the cAMP signaling pathway, although 
very prominent in maintaining proper balance between 
proliferation and differentiation of Schwann cells, does 
not work in a unitary manner, but rather orchestrates 
other pathways, i.e., PI3K‑AKT and MEK‑ERK kinase cas‑
cades (Fledrich et al. 2014) and neurosteroid‑mediated 
signaling (Gellersen and Brosens 2003, Magnaghi et al. 
2006) all of which are built around a common second 
messenger (Monje 2015). The targeting of multiple dis‑
ease‑relevant pathways by modulation of cAMP levels 
and inhibition of downstream effectors exerts a pleio‑
tropic mechanism of action in both Schwann cells and 
neurons. Firstly, it leads to an imbalance between ac‑
tivity of PI3K‑AKT and MEK‑ERK cascades, favoring the 
latter. This in turn causes upregulation of dedifferen‑
tiation markers c‑Jun and Sox‑2 and the downregula‑
tion of myelin gene expression, including PMP22, which 
maintains an immature proliferative Schwann cell phe‑
notype (Fledrich et al. 2014). Moreover, MEK‑ERK activ‑
ity induces upregulation of monocyte chemoattractant 
protein (MCP‑1 or CCL2), which attracts phagocytic 
macrophages, removing myelin debris and degenerat‑
ed axons from the site of injury (Martini 2014). Mar‑
tini et al. (2013) also observed that altogether those 
events are harmful for healthy nerves but might be 
advantageous in the context of disease‑injured axons. 
However, immaturity of Schwann cells that persists 
for a long time, along with defective differentiation, 
favors pathogenesis of CMT (Fledrich et al. 2014). In 
summary, dedifferentiation in pathological conditions 
is necessary but in intact axons is harmful. Secondly, 
activation of GPCRs and inhibition of cAMP signaling 
influences the excitability of neuronal cells and acti‑
vates cytoprotective signaling pathways. As mentioned 
previously, the lack of proper neuronal stimulation of 
Schwann cells does not promote myelination (Wake et 
al. 2015); however, it may be advantageous for axon 
regeneration as excessive excitability could lead to 
secondary nerve injuries in CMT patients. Saitoh et al. 
(2016) showed that activation of metabotropic gluta‑
mate receptor class 2 (mGluR2) promotes Schwann cell 
proliferation and de‑differentiation, while their inhi‑
bition promotes myelination by eliciting intracellular 
signaling downstream of a GPCR. Interestingly, mGluR2 
activation enhances NRG1‑induced ERK phosphoryla‑
tion that promotes proliferation and dedifferentiation 
of Schwann cells, but not Akt phosphorylation that re‑
sults in Schwann cell migration and/or sorting. mGluR 
signaling showed a significant effect on Schwann cell 
phenotype modulation in vivo. Thus, control of gluta‑
mate levels in peripheral nerve is crucial for Schwann 
cell proliferation, as well as differentiation. For this 
reason glutamate receptors could also contribute to the 
pathomechanism of CMT1A. Because differentiation of 
Schwann cells may counterbalance axon growth, ther‑
apy aiming to increase myelination should be applied 
independently of axon regenerating therapy or in later 
stages of regeneration (Monje 2015). As long as axons 
continue to grow, Schwann cells should be maintained 
in an immature state. Thus, highly important to any 
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pharmacological approach is the consideration of phys‑
iological chronology of individual processes. It appears 
that currently available therapies mainly aim for axon 
regeneration, and prolonged maintenance of Schwann 
cells in an undifferentiated state might be unfavorable 
for CMT phenotype alleviation.
CONCLUSIONS
Many of the currently available experimental ther‑
apeutics tested for effect in CMT1A in both pre‑clinical 
and clinical studies impact adenylyl cyclase activity, 
changing the physiology of Schwann cells and neurons. 
PXT3003, ADX71441, and, hypothetically, onapristone 
modulate adenylyl cyclase via GPCRs. In turn, AA acts 
as a competitive inhibitor of adenylyl cyclase activity. 
All compounds tested for CMT1A were equally prom‑
ising in pre‑clinical studies in terms of remyelination 
and decreasing PMP22 mRNA expression. However, they 
generally did not influence myelin thickness, which 
was increased only by AA administration and even in 
this case was only a minor improvement. Clinical tri‑
als that have been conducted with the use of AA did 
not show any significant effect on neuropathy com‑
pared with placebo after two years. However, the first 
and largest clinical trial established a systematic ap‑
proach in clinical assessment of CMT1A – the CMT neu‑
ropathic scale was introduced and large multicentre 
patient groups appeared. Onapristone was not tested 
for CMT1A in clinical trials due to severe side effects 
of previously conducted antiprogesterone treatment in 
women suffering from breast cancer. PXT3003 is cur‑
rently under investigation in phase 3 clinical trials. It 
was tested for safety and tolerability but showed only 
minor improvement in phase 2 trials. The most promis‑
ing compound in the treatment of CMT1A appears to be 
ADX71441, which exhibits the properties of previously 
tested drugs but additionally improves CMAP. More‑
over, it is a positive allosteric modulator of GABAB re‑
ceptor and, thus, more selective and potent than ortho‑
steric modulators. Applying new methods in structure 
based drug design to derive allosteric modulator drugs 
for the largest superfamily of cell surface receptors – 
GPCRs – should be a consideration in the future search 
for an effective CMT1A cure. 
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